Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Extended Low-Dose Apixaban Reduces Risk of Recurrent VTE: HI-PRO Trial Results
Sina Rashedi/X
Aug 30, 2025, 14:43

Extended Low-Dose Apixaban Reduces Risk of Recurrent VTE: HI-PRO Trial Results

Sina Rashedi, Postdoctoral Research Fellow at Brigham and Women’s Hospital, Harvard Medical School, shared a post on X:

”Honored to be a part of the HI-PRO trial, presented today by my mentor Gregory Piazza at ESC Congress 2025

Published in NEJM.

In provoked VTE and enduring risk,
Extended low-dose apixaban vs placebo:
Decreased risk of recurrent VTE with low risk of major.”

Read the full article here.

Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism

Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou,  John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber

Apixaban

Stay updated on the latest scientific advancements with Hemostasis Today.

Antoine Bejjani Apixaban Arvind K. Pandey Behnood Bikdeli Candrika D Khairani Darsiya Krishnathasan ESC Congress 2025 Gregory Piazza Heather Hogan Hemostasis Today HI-PRO trial John Fanikos Junyang Lou Lisa Rosenbaum Low-dose Apixaban Mariana Pfeferman Marie Gerhard-Herman NEJM Nicole Porio Piotr Sobieszczyk Provoked VTE Ruth H. Morrison Samuel Z. Goldhaber Sina Rashedi thrombosis Umberto Campia Zhou Lan
NewsFeed